LCS
SPRY icon

Levin Capital Strategies’s ARS Pharmaceuticals SPRY Stock Holding History

Levin Capital Strategies’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.4M Sell
548,965
-3,596
-0.7% -$30.9K 0.3% 79
2026
Q1 		$4.44M Sell
552,561
-194,945
-26% -$1.87M 0.34% 76
2025
Q4 		$8.71M Sell
747,506
-16,788
-2% -$163K 0.75% 41
2025
Q3 		$7.68M Buy
764,294
+475,147
+164% +$6.82M 0.69% 44
2025
Q2 		$5.05M Sell
289,147
-875,454
-75% -$12.6M 0.49% 49
2025
Q1 		$14.7M Buy
1,164,601
+696,974
+149% +$8.39M 1.55% 23
2024
Q4 		$4.93M Buy
467,627
+198,201
+74% +$2.78M 0.47% 51
2024
Q3 		$3.91M Buy
269,426
+186,176
+224% +$2.21M 0.37% 53
2024
Q2 		$708K Buy
83,250
+28,000
+51% +$248K 0.07% 100
2024
Q1 		$565K Buy
55,250
+3,000
+6% +$22.4K 0.06% 123
2023
Q4 		$286K Sell
52,250
-11,750
-18% -$51.5K 0.03% 192
2023
Q3 		$242K Sell
64,000
-105,074
-62% -$690K 0.03% 212
2023
Q2 		$1.13M Buy
169,074
+28,723
+20% +$192K 0.13% 86
2023
Q1 		$914K Buy
140,351
+101,341
+260% +$779K 0.11% 87
2022
Q4 		$333K Buy
+39,010
New +$253K 0.04% 153

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Levin Capital Strategies's SPRY Position: Q2 2026 in Review

Levin Capital Strategies reduced its ARS Pharmaceuticals (SPRY) stake by 0.65% in Q2 2026, selling an estimated $30.9K and leaving 548,965 shares worth $4.4M. The position accounts for 0.3% of the portfolio, ranked #79.

Levin Capital Strategies first reported a position in SPRY in Q4 2022 and has held it in 15 quarters since. The position peaked at $14.7M in Q1 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Levin Capital Strategies held 548,965 shares of ARS Pharmaceuticals worth $4.4M as of Q2 2026.
  • Levin Capital Strategies sold 3,596 ARS Pharmaceuticals shares in Q2 2026, an estimated $30.9K.
  • ARS Pharmaceuticals made up 0.3% of Levin Capital Strategies's portfolio in Q2 2026, its #79 holding.
  • Levin Capital Strategies first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Levin Capital Strategies's ARS Pharmaceuticals position peaked at $14.7M in Q1 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Levin Capital Strategies's 13F filing for Q2 2026, filed 31 Jul 2026.